Ligand Partner Retrophin Announces Positive Top-Line Results from Phase 2 DUET Study of Sparsentan in Patients with Focal Segmental Glomerulosclerosis September 7, 2016
Results from Phase 1 Trials with Ligand’s LGD-6972 in Type 2 Diabetes Mellitus Published in Diabetes, Obesity and Metabolism August 15, 2016
Ligand Announces Multi-Program LTP Technology Licensing Agreement with Nucorion Pharmaceuticals July 29, 2016
Ligand Acquires Portfolio of Synthetic Royalty and Milestone Rights from CorMatrix® Cardiovascular for $17.5 Million May 4, 2016
Ligand Announces First Quarter 2016 Earnings Reporting Date and Participation in Four Upcoming Investor Conferences April 22, 2016
Revolade® Approved in EU as First in Class Therapy for Children Aged 1 Year and Above with Chronic ITP April 7, 2016